Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
1.160
-0.010 (-0.85%)
At close: Sep 3, 2026, 4:00 PM EDT
1.160
0.00 (0.00%)
After-hours: Sep 3, 2026, 4:00 PM EDT

Indaptus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.5610.498.118.768.595.21
Research & Development
5.229.347.257.626.322.52
Operating Expenses
14.7719.8315.3716.3814.917.73
Operating Income
-14.77-19.83-15.37-16.38-14.91-7.73
Other Non Operating Income (Expenses)
-0.65-1.020.340.960.590.02
Pretax Income
-15.42-20.85-15.02-15.42-14.32-7.71
Net Income
-15.42-20.85-15.02-15.42-14.32-7.71
Net Income to Common
-15.42-20.85-15.02-15.42-14.32-7.71
Net Income Growth
------
Shares Outstanding (Basic)
3310000
Shares Outstanding (Diluted)
3310000
Shares Change
7142.37%189.14%11.36%1.68%101.98%110.35%
EPS (Basic)
-0.47-21.58-44.96-51.41-48.54-52.78
EPS (Diluted)
-0.47-21.58-44.96-51.41-48.54-52.78
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-14.7-14.82-12.32-13.41-13.08-11.29
Free Cash Flow Per Share
-0.45-15.34-36.88-44.68-44.32-77.31
EBITDA
--19.83-15.37-16.38-14.91-7.73
D&A For EBITDA
-00000
EBIT
-14.77-19.83-15.37-16.38-14.91-7.73
SEC Filings: 10-K · 10-Q